Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL
about
Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based StudyAbility of two commercially available assays (Abbott RealTime HIV-1 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2.0) to quantify low HIV-1 RNA Levels (<1,000 copies/milliliter): comparison with clinical samples and NIBSC working reagent forSignificance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.A Simple Phosphate-Buffered-Saline-Based Extraction Method Improves Specificity of HIV Viral Load Monitoring Using Dried Blood Spots.Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation.Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia.True durability: HIV virologic suppression in an urban clinic and implications for timing of intensive adherence efforts and viral load monitoring.HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity.Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant PartnershipsQuantification of viral loads lower than 50 copies per milliliter by use of the Cobas AmpliPrep/Cobas TaqMan HIV-1 test, version 2.0, can predict the likelihood of subsequent virological rebound to >50 copies per milliliter.A Single Quantifiable Viral Load Is Predictive of Virological Failure in Human Immunodeficiency Virus (HIV)-Infected Patients on Combination Antiretroviral Therapy: The Austrian HIV Cohort StudyAntiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA PanelTemporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment servicePoor retention in care one-year after viral suppression: a significant predictor of viral rebound.Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study.Evaluation of the Aptima(®) HIV-1 Quant Dx assay for HIV-1 RNA viral load detection and quantitation in plasma of HIV-1-infected individuals: A comparison with Abbott RealTime HIV-1 assay.Reduced adherence to antiretroviral therapy is associated with residual low-level viremia.European Multicenter Study on Analytical Performance of Veris HIV-1 Assay.Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice.Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.Comparing HIV viral load assays and frequency of low level virological rebound in clinical practice.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
P2860
Q33653518-E8A98531-3C84-4F49-AD68-8C61AEF145B3Q33703537-CEDBA2E9-23A8-473D-B389-329661F5CC23Q33798584-366BCEC5-48C3-41CB-AEDD-ACF2FC538C97Q33832833-99815977-4FD6-4BE6-B9D1-68621AEB77D3Q34288534-39BCAB79-7443-478F-8790-FEAEAD412B4CQ34324005-E2AD9F86-0E24-4665-8E96-2B7531D16DD3Q35349912-23914629-9B7E-4E02-B853-AA571FB82222Q35698144-35AC8DF7-4FD5-4918-8766-561254BACE2FQ35868687-EF75E010-5B7B-4A62-8638-CA62FD286C43Q36602040-0ACDF660-94C3-4438-8BC3-E698C228EFDFQ36826684-FBC8D5F7-D301-4C9B-BC3F-48651F44654DQ37091685-7336FD6A-6BEC-4A31-9DE1-078B84841307Q37234729-7D35471A-35FF-4741-AC67-94CBAA9A0DF5Q37284765-F3824184-7039-4826-B1EF-E81224FCF3FCQ38213484-4596C46A-C0BD-4656-AC2D-DE131255C262Q39375437-32098C84-F1AD-4270-8624-38C07033470DQ40007100-82D11102-086D-4F95-8DA1-A1F9BACBD108Q40164081-D2D3A71A-54AA-4E0D-8A0C-7B130D4A2615Q40235669-F9DDDEF2-66E4-4666-AFD1-BE0970AD65F2Q40593936-45AC4176-5BD7-4DC3-9E81-47E5721478D2Q41276669-9A7E8073-9BDB-45A2-B558-260A26C13CA6Q42211136-E77EC191-31DE-4DF9-AB80-C10F8455B738Q42230298-8983C303-3B4D-43A7-BFE1-44C7BCB0130AQ57180790-7E279F6C-7CA9-40FD-81DD-0203A5FF6DF4
P2860
Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Increased risk of virologic re ...... ectable HIV load <48 copies/mL
@ast
Increased risk of virologic re ...... ectable HIV load <48 copies/mL
@en
Increased risk of virologic re ...... ectable HIV load <48 copies/mL
@nl
type
label
Increased risk of virologic re ...... ectable HIV load <48 copies/mL
@ast
Increased risk of virologic re ...... ectable HIV load <48 copies/mL
@en
Increased risk of virologic re ...... ectable HIV load <48 copies/mL
@nl
prefLabel
Increased risk of virologic re ...... ectable HIV load <48 copies/mL
@ast
Increased risk of virologic re ...... ectable HIV load <48 copies/mL
@en
Increased risk of virologic re ...... ectable HIV load <48 copies/mL
@nl
P2093
P2860
P1433
P1476
Increased risk of virologic re ...... ectable HIV load <48 copies/mL
@en
P2093
Brian R Wood
Daniel R Kuritzkes
Timothy J Henrich
P2860
P304
P356
10.1371/JOURNAL.PONE.0050065
P407
P577
2012-11-15T00:00:00Z